WAIKOLOA, Hawaii — A gene-based therapy, specifically designed to neutralize VEGF activity, may be the next approach to the treatment of diabetic retinopathy, with the advantage of a single suprachoroidal administration.
Anti-VEGF treatment in eyes with nonproliferative diabetic retinopathy without diabetic macular edema has shown to be effective in both the PANORAMA trial and the DRCR.net Protocol W. However, the Achilles’ heel of this treatment is the burden of multiple injections, Michael S. Ip, MD, said at Retina 2022.
RGX-314 (Regenxbio) is a novel gene therapy that uses an